简介:目的对人唾液腺腺样囊性癌肺高转移细胞株(ACC-M)和肺低转移细胞株(ACC-2)差异表达的部分基因进行克隆和蛋白表达研究.方法应用cDNA基因表达谱芯片,对ACC-2及ACC-M细胞所检测的基因差异表达数据,结合NCBI和生物信息学软件分析技术,利用RT-PCR方法,克隆ACC-2和ACC-M表达有显著差异基因的EST,将得到的EST重组至质粒PET-24a-d(+)中,构建表达质粒;质粒转化大肠杆菌BL21,经IPTG诱导后表达目的蛋白.结果克隆了RAB7L1、h4F2hc、G8、L6、K1AA0119共5个差异表达基因,成功构建表达载体,EST测序结果与GeneBank对照一致,5个EST均可表达目的蛋白.结论从ACC-2和ACC-M细胞差异表达基因中,可克隆到能够表达目的蛋白的新基因,这些基因可能与腺样囊性癌转移表型产生有关.
简介:In2014theAmericanCollegeofCardiology/AmericanHeartAssociationissuedfournewguidelinesforcardiovasculardiseasepreventionthatfocusedoncardiovascularriskassessment,lifestylemanagement,obesitymanagement,andbloodcholesterolmanagement.Thedevelopmentofanatheroscleroticcardiovasculardiseaseriskcalculatorformedthebasisoftheriskassessmentguideline,andthelifestylemanagementguidelinefocusedonrecommendinganevidence-baseddietarypattern.Thebloodcholesterolmanagementguidelinespecificallyidentifiedfourgroupsofpatientsshowntobenefitfrommoderate-intensityorhigh-intensitystatintherapyfrompreviousclinicaltrialsandabandonedtheuseofspecificlow-densitylipoprotein(LDL)cholesterol(LDL-C)goallevelsonthebasisofthelackofclinicaltrialevidence.Therecommendationsfortreatmentwithmoderate-intensityorhigh-intensitystatintherapyarebasedonrigorousevidencefromrandomizedclinicaltrials.Guidancehassincebeenprovidedfortheuseofnonstatintherapies,includingcholesterolabsorptioninhibitorandproproteinconvertasesubtilisin/kexintype9monoclonalantibodytherapywhenadequatereductionofLDL-Clevelsisnotachievedwithmaximallytoleratedstatintherapy.TherecentdevelopmentandapplicationofthesetherapieshaveresultedinremarkablereductionsinLDL-Clevelsthatarewelltolerated,andpreliminaryoutcomedataarepromisinginshowingsubstantialatheroscleroticcardiovasculardiseaseeventreductionsbeyondstatintherapy.
简介:In2003,IwasinvitedtoattendandpresentascientificpaperattheGWICCmeetinginBeijing,China,byProfessorHuDayi.AtthetimeProfHuwaschiefofcardiologyinBeijingandDeanofamedicalschoolinShanghai.ThisconferencewasandstillisthelargestcardiologyeducationalandscientificprograminChinaandisattendedbymorethantenthousandpersons,mostlyChinese,butalsoEuropeans,Americans,andothernationalities.
简介:无
简介:Take-homeMessages.TherecentlypublishedACC/AHAcholesterolguidelinesrecommendfixed-dosestatintherapyforthoseatrisk,andalthoughnotrecommendedasfirstlinetherapy,nonstatintherapiesarerecommendedwhenlessthananticipatedtherapeuticresponsetostatintherapyoccursorwhenpatientsarenotabletotoleratestatintherapy.Nonstatincholesterol-loweringdrugsshowntoreduceatheroscleroticcardiovasculardisease(ASCVD)eventsinrandomizedcontrolledtrials(RCTs)arepreferred.Noevidencewasfoundtosupporttheuseofspecificlow-densitylipoprotein(LDL)-cholesteroltargetlevels.
简介:摘要 目的 探讨杜仲多糖通过调控腺苷酸活化蛋白激酶(AMPK)/乙酰辅酶A羧化酶(ACC)通路对2型糖尿病大鼠的影响。方法:高脂高糖饮食联合小剂量链脲佐菌素(STZ)腹腔注射建立2型糖尿病模型,并将造模成功大鼠随机分为模型组、低剂量组、高剂量组和二甲双胍组,另设正常组。低和高剂量组大鼠分别灌胃100 和200 mg/kg杜仲多糖溶液,二甲双胍组大鼠灌胃二甲双胍片溶液0.25 g/kg,正常组和模型组大鼠则灌胃等量生理盐水,1次/d,连续30 d。测量大鼠体重和空腹血糖(FBG)水平,全自动生化分析仪检测总胆固醇(TC)、甘油三酯(TG)和游离脂肪酸(FFA)水平,ELISA法检测血清胰岛素(FINS)水平,计算胰岛素抵抗指数(HOMA-IR),硫代巴比妥酸比色分析法检测丙二醛(MDA)水平和谷胱甘肽过氧化酶(GSH-Px)活性,黄嘌呤氧化酶法检测超氧化物歧化酶(SOD)活性,蛋白印迹法检测p-AMPK和p-ACC蛋白表达量。结果:与模型组比较,低、高剂量组和二甲双胍组大鼠体重升高,FBG、TC、TG、FFA、FINS和HOMA-IR水平均降低,MDA含量降低,SOD和GSH-Px活性以及p-AMPK和p-ACC蛋白表达量升高(P<0.05);与低剂量组比较,高剂量组和二甲双胍组大鼠体重升高,FBG、TC、TG、FFA、FINS和HOMA-IR水平均降低,MDA含量降低,SOD和GSH-Px活性以及p-AMPK和p-ACC蛋白表达量升高(P<0.05);与高剂量组比较,二甲双胍组大鼠体重升高,FBG、TC、TG、FFA、FINS和HOMA-IR水平均降低,MDA含量降低,SOD和GSH-Px活性以及p-AMPK和p-ACC蛋白表达量升高(P<0.05)。结论:杜仲多糖可降低2型糖尿病大鼠血糖水平,改善血脂代谢,发挥肝脏保护作用,增强胰岛素敏感性,其可能是通过激活AMPK/ACC通路发挥作用。